Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (231-240 of 355) with videos related to

Pageof 36
Sort By:
AIDS (London, England)|April 19, 2015
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccinationAs'ad E Bhorat, Shabir A Madhi, France Laudat, et al.
Vaccine|September 18, 2007
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccinesPeter F Wright, Ruth A Karron, Robert B Belshe, et al.
Vaccine|May 31, 2011
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 yearsT F Schwarz, J Flamaing, H C Rümke, et al.
Vaccine|March 13, 2025
A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccineFederico Martinón-Torres, Silvina Natalini Martinez, Mary J Kline, et al.
Nature Communications|December 15, 2021
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adultsMiwa Haranaka, James Baber, Yoichiro Ogama, et al.
Biochimica Et Biophysica Acta|February 13, 2016
Crystal structure of the Saccharomyces cerevisiae monoglyceride lipase Yju3pPhilipp Aschauer, Srinivasan Rengachari, Joerg Lichtenegger, et al.
Human Vaccines & Immunotherapeutics|August 7, 2023
A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of ageKai Chu, Yuemei Hu, Hongxing Pan, et al.
Vaccine|May 22, 2013
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and olderLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Nature Communications|June 24, 2014
Identification of promiscuous ene-reductase activity by mining structural databases using active site constellationsGeorg Steinkellner, Christian C Gruber, Tea Pavkov-Keller, et al.
Vaccine|June 4, 2019
A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the NetherlandsBradford D Gessner, Qin Jiang, Cornelis H Van Werkhoven, et al.
Pageof 36

Showing results (231-240 of 355) with videos related to

Sort By:
Pageof 36
AIDS (London, England)|April 19, 2015
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccinationAs'ad E Bhorat, Shabir A Madhi, France Laudat, et al.
Vaccine|September 18, 2007
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccinesPeter F Wright, Ruth A Karron, Robert B Belshe, et al.
Vaccine|May 31, 2011
A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 yearsT F Schwarz, J Flamaing, H C Rümke, et al.
Vaccine|March 13, 2025
A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccineFederico Martinón-Torres, Silvina Natalini Martinez, Mary J Kline, et al.
Nature Communications|December 15, 2021
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adultsMiwa Haranaka, James Baber, Yoichiro Ogama, et al.
Biochimica Et Biophysica Acta|February 13, 2016
Crystal structure of the Saccharomyces cerevisiae monoglyceride lipase Yju3pPhilipp Aschauer, Srinivasan Rengachari, Joerg Lichtenegger, et al.
Human Vaccines & Immunotherapeutics|August 7, 2023
A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of ageKai Chu, Yuemei Hu, Hongxing Pan, et al.
Vaccine|May 22, 2013
Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and olderLisa A Jackson, Alejandra Gurtman, Martin van Cleeff, et al.
Nature Communications|June 24, 2014
Identification of promiscuous ene-reductase activity by mining structural databases using active site constellationsGeorg Steinkellner, Christian C Gruber, Tea Pavkov-Keller, et al.
Vaccine|June 4, 2019
A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the NetherlandsBradford D Gessner, Qin Jiang, Cornelis H Van Werkhoven, et al.
Pageof 36